The psychedelic drug LSD is poised to become the next big thing in treating generalized anxiety disorder. On Wednesday morning, Definium Therapeutics announced the primary findings from a Phase III trial testing its proprietary version of LSD, named DT120. Compared to people taking a placebo, those on DT120 saw a noticeable decline in their anxiety symptoms, the trial showed. It’s the second large-scale trial success for Definium and DT120 in recent months, both of which should pave the way for LSD to become an approved psychiatric treatment in the near future. LSD as medicine LSD (short for lysergic acid diethylamide) is a semisynthetic drug derived from the ergot fungus and is well known for its psychedelic and hallucinogenic effects. It’s usually taken as an oral dissolving tablet, with its effects typically lasting between 6 and 12 hours, depending on the dosage. In recent years, LSD has received (renewed) attention from scientists as a potential medication for various mental health conditions. Definium, previously known as MindMed, has been developing DT120 as a treatment for major depressive disorder and generalized anxiety disorder (GAD). In late June, the company released the results of its randomized double-blinded, placebo-controlled Emerge trial, which showed that people taking a single dose of DT120 experienced a significantly greater reduction in their depression symptoms than those taking a placebo.